Research progress in triple-negative breast cancer
- VernacularTitle:ER、PR、HER-2阴性乳腺癌研究进展
- Author:
Yan LIU
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Drug therapy;
Molecular biology
- From:
Journal of International Oncology
2008;35(7):496-499
- CountryChina
- Language:Chinese
-
Abstract:
"Triple-negative"breast cancer patients who have special clinicopathological characteristics are defined by a lack expression of oestrogen,progesterone,and HER-2 receptors.Triple-negative patients usually metastasize early with worse prognosis,and have a higher incidence of visceral metastases than bony metas tases.This subgroup has no chance of hormone treatment and targeted therapy for HER-2,and chemotherapy is the main therapy.We discuss the predominant proliferative signals,molecular features of triple-negative breast cancer,and some basic studies and clinical trials.Furthermore,targeted therapy against EGFR,C-kit,and BRCA1 may show preferable anticancer activity.However,recent research is still unable to identify the biological characteristics of triple-negative Cancer,and special treatment is still not available.
